Brought to you by 
RegeneRx, G-treeBNT create JV around ophthalmic candidate RGN259
06 Aug 2018
Executive Summary
Teaming up for the second time, RegeneRx Biopharmaceuticals Inc. and G-treeBNT Co. Ltd. (formerly Digital Aria) created a yet-to-be named joint venture that will hold exclusive US rights to the former's Phase II RGN259 for dry eye and the orphan condition neurotrophic keratitis, a degenerative corneal epithelium disease. NOTES: The joint venture is called ReGenTree LLC. RGN259 is also known under other names, including thymosin beta-4, GBT101, GBT201, RGN137 RGN352, and RGN457.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RegeneRx, G-treeBNT create JV around ophthalmic candidate RGN259
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice